Drugs / ASP3325
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02510274 | May → Nov 2014 | chronic kidney disease, hyperphosphatemia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02500953 | Jul → Dec 2013 | — | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP3325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02510274 ↗ |
| Route | Oral | “ASP3325 will be administered as a single oral dose with 240 mL of water” NCT02500953 ↗ |